Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire

被引:207
作者
Cappelleri, Joseph C.
Bushmakin, Andrew G.
Baker, Christine L.
Merikle, Elizabeth
Olufade, Abayomi O.
Gilbert, David G.
机构
[1] Pfizer Inc, Global Res & Dev, Groton, CT 06340 USA
[2] Pfizer Inc, New York, NY USA
[3] Pfizer Canada Inc, Kirkland, PQ, Canada
[4] So Illinois Univ, Carbondale, IL 62901 USA
关键词
modified cigarette evaluation questionnaire; mCEQ; smoking; varenicline; reinforcing effects;
D O I
10.1016/j.addbeh.2006.06.028
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
We examined the validity and reliability of the modified Cigarette Evaluation Questionnaire (mCEQ) that assesses the degree to which subjects experience the reinforcing effects of smoking. Data came from three phase II clinical trials (n=626, n=627, n=312) on varenicline for smoking cessation. Comparative fit indexes and non-normed fit indexes from a confirmatory factor analysis exceeded 0.90. Cronbach's alpha for internal consistency reliability exceeded 0.70 for the Smoking Satisfaction domain and the Psychological Reward domain but was less than 0.70 for the Aversion domain; test-retest reliability generally exceeded 0.70 on the three multi-item domains and two single items. The validity and, in general, the reliability of the postulated multidimensional framework of the mCEQ are confirmed and supported by the analyses of three independent studies, with multi-item domains on Smoking Satisfaction (satisfying, taste good, enjoy smoking), Psychological Reward (calm down, more awake, less initable, help concentrate, reduce hunger), and Aversion (dizziness, nauseous), as well as the single-item assessment on Enjoyment of Respiratory Tract Sensations and on Craving Reduction. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:912 / 923
页数:12
相关论文
共 11 条
[1]  
[Anonymous], EZPATH CAUSAL MODELI
[2]   Nicotine addiction [J].
Benowitz, NL .
PRIMARY CARE, 1999, 26 (03) :611-+
[3]  
HATCHER L, 1994, STEP BY STEP APPROAC
[4]  
HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119
[5]  
Klein R.B., 2005, PRINCIPLES PRACTICE, V2nd
[6]   Nicotine-mecamylamine treatment for smoking cessation: The role of pre-cessation therapy [J].
Rose, JE ;
Behm, FM ;
Westman, EC .
EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, 1998, 6 (03) :331-343
[7]   MECAMYLAMINE COMBINED WITH NICOTINE SKIN PATCH FACILITATES SMOKING CESSATION BEYOND NICOTINE PATCH TREATMENT ALONE [J].
ROSE, JE ;
BEHM, FM ;
WESTMAN, EC ;
LEVIN, ED ;
STEIN, RM ;
RIPKA, GV .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (01) :86-99
[8]  
SAS Institute, 1999, SAS STAT US GUID
[9]   Immediate hedonic response to smoking lapses: relationship to smoking relapse, and effects of nicotine replacement therapy [J].
Shiffman, S ;
Ferguson, SG ;
Gwaltney, CJ .
PSYCHOPHARMACOLOGY, 2006, 184 (3-4) :608-618
[10]  
*US DEPH HHS USDHS, 1988, HLTH CONS SMOK NIC A